Alamar Biosciences (NASDAQ: ALMR) is a commercial-stage proteomics company that develops and sells instruments, consumables, and software for protein biomarker detection and analysis. Revenue comes primarily from sales of its ARGO HT instrument, associated consumables, and service revenue from its TAP (sample testing and analysis program), plus instrument maintenance contracts. The company commercially launched the ARGO HT System in January 2024 and had accumulated more than 300 customers across 25 countries with a cumulative installed base of over 100 instruments as of the Q1 2026 10-Q filing. The platform is built around proprietary NULISA technology, designed to detect low-abundance protein biomarkers in non-invasive biological fluids such as blood. Instrument sales function as the primary growth driver and a leading indicator of future consumables revenue, creating a razor-and-blades revenue dynamic. The company operates at a net loss and relies on continued capital investment to fund product development and sales expansion.

Revenue model

Instrument sales (ARGO HT System), consumables tied to the installed instrument base, service revenue from the TAP sample-testing program (NULISA multiplex and single-plex assays with delivered analytical reports), and instrument maintenance contracts. Instrument revenue drives consumables pull-through over time.

Products and services

ARGO HT System (proprietary proteomics instrument, commercially launched January 2024); NULISA technology (multiplex and single-plex protein biomarker assays); consumables for the ARGO HT platform; TAP (testing-as-a-service program for sample analysis prior to or alongside instrument purchase); instrument maintenance contracts; analytical software for end-to-end proteomics workflows.

Customers and end markets

Life sciences researchers across discovery, translational research, and diagnostics development. More than 300 customers across 25 countries as of the Q1 2026 10-Q filing. Sales cycles are lengthy because instrument purchases represent major capital expenditures requiring senior management approval.

Value-chain role

Instruments and reagents manufacturer and technology platform provider. Sells directly to research customers. Also operates an in-house sample-testing lab (TAP) for service-based assay delivery. Relies on third-party suppliers for components and cloud-based infrastructure.

Geographic exposure

Sells across 25 countries as of the Q1 2026 10-Q filing. Specific country-level revenue breakdown not disclosed in the filing excerpts.

Source: SEC 10-Q, filed 2026-05-08

Industry: Laboratory Analytical Instruments